Thanks for reaching out

We will be in-touch shortly. In the meantime, check out some of the recent posts on the COTA blog.

COTA, Inc. Forms Strategic Real-World Data Research Partnership with the Clinical Research Data Sharing Alliance

COTA, Inc. is now a proud member of the Clinical Research Data Sharing Alliance (CRDSA). This cross-industry alliance is dedicated to accelerating the discovery and delivery of life-saving therapies through the use of high-quality clinical trials and real-world data.

READ MORE

What Makes a Fit-for-Purpose Database for Clinical Oncology Research?

A fit-for-purpose database includes key variables, reliable and accurate data, and representative samples that can be used to draw meaningful conclusions. RWD can be highly valuable in supporting clinical oncology research, but choosing the right data is essential. The keys to finding the right fit-for-purpose database include relevance, reliability, integrity, and bias.

READ MORE

How Real-World Data Helps Explore Alternative Dosing for Colorectal, Pancreatic Cancer Therapy

Research from MedStar Georgetown Lombardi Comprehensive Cancer Center and COTA shows the potential of a more patient-friendly dosing regimen for Stage 4 CRC/PC or locally advanced PC.
This collaboration highlights how real-world data can contribute to clinical research and can help answer pressing questions about care already taking place in clinical practice.

READ MORE

Key Takeaways from ASH 2022: Real-World Data Gets Down to Business

The American Society of Hematology’s 2021 annual meeting showed that real-world data is no longer the new kid on the block – it’s an indispensable part of the toolkit for therapeutic development and clinical research. COTA is proud to be a part of the discussion, contributing research this year for chronic lymphocytic leukemia.

READ MORE

Are Pharma Companies Ready to Harness the Promises of Real-World Data?

Partnering with Impatient Health, we take a comprehensive look at the realities of real-world data and the challenges that pharma companies face in leveraging it to gain actionable insight, based on feedback from executives at well-known, major pharma companies.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.

READ MORE

The Power of Collaboration: ASH Showcases COTA’s Real World Data and Research at Annual Meeting

COTA is honored to have contributed to three abstracts accepted for poster presentation at the American Society of Hematology’s 64th Annual Meeting, which cover a range of hematologic cancers. These studies focus on patient- and clinician-reported performance status in Multiple Myeloma, and real-world treatment patterns among patients with newly diagnosed Acute Myeloid Leukemia in the US.

READ MORE

Subscribe for Updates

Receive our latest news and research from thought leaders in the RWD industry
  • This field is for validation purposes and should be left unchanged.